| Ytd | 96.68% | |
| 1y | 260.98% |
| Open | 5.90 | Prev Close | 5.90 | Low | 5.80 | High | 5.93 | Mkt Cap | 826.81M |
| Vol | 1.23M | Avg Vol | 1.81M | EPS | -0.58 | P/E | -10.21 | Forward P/E | -5.00 |
| Beta | 0.12 | Short Ratio | 0.47 | Inst. Own | 90.21% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 5.14 | 200-d Avg | 3.86 | 1yr Est | 10.00 |
ACRS News
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical res
WAYNE, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Conse
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which beat the ana
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Pote
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The lat
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
Investing in penny stocks requires significant conviction. Many of the companies in this group are p
U.S. stock futures mixed. SL Science shares fall 11.4% after reporting financial results. Other stoc
Investing in penny stocks requires significant conviction. Many of the companies in this group are p
Aclaris Therapeutics NASDAQ: ACRS executives outlined a busy clinical calendar for the biotechnology
Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two
WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-s
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Tran
WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-s
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Conse
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the anal
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Valid
Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight a
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit
Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with
Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and ra
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific
"These results validate that ATI-052 is a highly potent and well tolerated bispecific antibody t
- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed A
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve
WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical
Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Ou
Aclaris Therapeutics, Inc. (NASDAQ: ACRS - Get Free Report) saw a significant increase in short inte
WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical
Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and m
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Me
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Me
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve
WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the a
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Ph
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)
Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce
Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.12) per share which beat the ana
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve
- Late Breaking Abstract to Present Additional Data from Aclaris' Phase 2a Trial of ATI-2138 in
U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indic